trending Market Intelligence /marketintelligence/en/news-insights/trending/1BEy6tinzpozqueU__5trA2 content
Log in to other products

Login to Market Intelligence Platform

 /

Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

US FDA approves Roche's lung cancer companion diagnostic

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


US FDA approves Roche's lung cancer companion diagnostic

The U.S. Food and Drug Administration approved Roche Holding Ltd.'s VENTANA ALK (D5F3) CDx Assay as a companion diagnostic to identify anaplastic lymphoma kinase-positive non-small cell lung cancer patients eligible for treatment with Novartis AG's Zykadia drug.

The in vitro diagnostic assay will be used to detect the anaplastic lymphoma kinase protein in non-small cell lung carcinoma tissue on BenchMark XT or BenchMark ULTRA automated staining instrument. It is the only immunohistochemistry test approved by the FDA as a companion diagnostic for Zykadia.